most in Medical Technology

Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation

St. Jude study shows personalized chemotherapy can improve cure rate and avoid the use of radiation in acute lymphoblastic leukemia treatment MEMPHIS, Tenn., June 24 /PRNewswire-USNewswire/ -- Childhood acute lymphoblastic leukemia (ALL) can be successfully treated using a carefully person...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

Start of trial triggers $10 million milestone payment to Pharmasset PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today announced that the first patient has been dosed in a Phase IIb study of R7128, th...

Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study

SYDNEY, Australia, Feb. 26 /PRNewswire/ -- Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes...

American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks

Association's Mission: Lifeline initiative to use survey data to make improvements DALLAS, Feb. 16 /PRNewswire-USNewswire/ -- Preliminary results of one of the nation's largest national surveys of Emergency Medical Services (EMS) systems indicate the need for improvements in the way heart att...

New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease

BALTIMORE, Jan. 27 /PRNewswire/ -- Most Americans know their cholesterol level, but do they know how "sticky" their platelets are? Research findings from Dr. Paul A. Gurbel, an interventional cardiologist and Director of the Sinai Center for Thrombosis Research based at Sinai Hospital of Baltimor...

Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer

Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is Inconsistent, According to a New Report from Decision Resources WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issu...

Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection

CE IVD Menu Expanded to Eight On-Demand Tests for Use on the GeneXpert(R) System SUNNYVALE, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced the release of Xpert(TM) vanA/vanB as a European CE IVD Mark product under the European Dir...

Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels

ROCKVILLE, Md., Sept. 15 /PRNewswire-USNewswire/ -- Pre-mixed insulin analogues, a modified form of conventional pre-mixed human insulin, are more effective than long-acting analogues for controlling high blood sugar levels after meals in patients with type 2 diabetes, according to a report fu...

AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.

SAN MATEO, Calif., July 8 /PRNewswire/ -- After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk. 85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to A...

More Than 1.5 Million Americans Sickened, Injured or Killed by Medication Errors Each Year; Seniors Most at Risk

DailyMed(TM) Launches Innovative Solution to Medication Mismanagement Epidemic NEW YORK, Jan. 28 /PRNewswire/ -- Acute consequences of medication mismanagement continue to mount, emphasizing the urgent need for a systematic change in the way we care for the 38+ ...

Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes

Doctors Are Combining Portrait(R) Plasma with Fractionated Lasers Or in Place of Surgery to Alleviate the Signs of Aging of the Eyes WALTHAM, Mass., Jan. 24 /PRNewswire/ -- When it comes to the aging eye area, going under the knife is no longer the only option. According to the American A...

Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins

Study Designed to Determine Statin Effects on Regression of Atherosclerosis CLEVELAND, Jan. 15 /PRNewswire/ -- Cleveland Clinic researchers will coordinate the first head-to-head comparison of the two most powerful statin medications. The trial intends to begin enrollment as early as next week. ...

Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio

Seek-Find-Act-Follow: Innovations Span Entire Breast Care Continuum, from Early Detection and Diagnosis, to Targeted Therapy, Monitoring and After Care CHICAGO, Nov. 25 /PRNewswire-FirstCall/ -- Siemens Medical Solutions (http://www.usa.siemens.com/medical ) ...

New Data Published in The Lancet Show GSK's ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types

Protection Sustained During the First Two Years of Life PHILADELPHIA, Nov. 23 /PRNewswire-FirstCall/ -- New data from a large European clinical trial published today in The Lancet show ROTARIX(R), GlaxoSmithKline's (NYSE: GSK ) oral rotavirus candidate vaccine to prevent rotavirus gas...

New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need

WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- The following statement was released today by Pamela W. Barnes, President and Chief Executive Officer of the Elizabeth Glaser Pediatric AIDS Foundation: "Four years after the President's Emergency Plan for AIDS Relief (PEPFAR) began funding trea...

Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations

The once-daily HIV treatment would greatly increase effectiveness for patients, but Gilead Sciences and Merck and Co. have failed to register it in countries where it is needed most LOS ANGELES, Sept. 10 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today calle...

Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually

April is STD Awareness Month: Time to Pay Attention to this Overlooked Disease SAN ANTONIO, Texas, April 02, 2007 /PRNewswire/ -- During National Sexually Transmitted Disease (STD) Awareness Month this April, Mission Pharmacal is urging increased awareness of, and testing for, trichomoniasis (also...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p - Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels - Detailed results presented today at the Seventeenth European Meeting on Hypertension in Mil...

Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types

Results also show significant additional protection against infection with virus types beyond 16 and 18 with the GSK cervical cancer candidate vaccine PHILADELPHIA, June 27, 2007 /PRNewswire-FirstCall/ -- Results from an interim analysis of a Phase III study show that CERVARIX(R), the GlaxoSmithKl...

Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases

... hinder normal vision. Currently, drugs for most retinal diseases are delivered either through an I...generally ineffective for retinal diseases because most medications are washed away or diluted before they...ldren's Hospital Los Angeles has been treating the most seriously ill and injured children in Los Angeles ...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

...orectal Cancer Colorectal cancer is the fourth most common cancer in men and the third most common cancer in women worldwide. In 2007, approxi...on (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...rsen will reach the patients who need the drug the most first, and provide commercial experience with mipo... Drug Development Highlights Mipomersen, the most advanced drug in Isis' cardiovascular pipeline, is...10-K for the year ended December 31, 2008, and its most recent quarterly report on Form 10-Q, which are on...

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

... the Novartis Research Foundation (GNF) to create a diabetes drug discovery and development platform. The four-year program is one of the largest and most comprehensive collaborations in the 40 year history of JDRF, a leader in setting the agenda for diabetes research worldwide and the largest charitable...

Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis

... especially encouraged by BA058's superior efficacy in building new bone rapidly, particularly at the femoral neck, since hip fractures are one of the most serious complications of osteoporosis and an area in which currently available osteoporosis treatments are weak." "These data are consistent w...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...uarterly Report on Form 10-Q for the quarter ended March 31, 2009 filed with the Securities and Exchange Commission on May 8, 2009, and the company's most recent Quarterly Report on Form 10-Q to be filed on or about August 5, 2009. Actual results could differ materially from the forward-looking statemen...

DNA Helps Reunite Children With Their Families

...tional repository of these DNA profiles. Then DNA- PROKIDS will become a deterrent and prevent criminals from kidnapping and trafficking children, the most vulnerable of all victims. About the University of North Texas Health Science Center The University of North Texas Health...

ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer

...w.aruplab.com. "In the United States, colorectal cancer is the third most common form of cancer and individuals have a 6 percent lifetime risk of dev...ne whether a particular therapeutic strategy should be used by oncologists. most colorectal cancer is caused by somatic mutations and is not hereditary. Mut...

CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research

...ject approval, CTMM has fulfilled the initial objectives of its business plan by establishing public-private research consortia to address the world's most prevalent diseases. The CTMM project portfolio now comprises 18 projects conducting translational molecular medicine research into innovative new tech...

Scientists Discover Origin of Malaria

...e known to harbor a parasite, called Plasmodium reichenowi , that is closely related to the dominant human malaria parasite, Plasmodium falciparum , most scientists assumed incorrectly that these parasites had co-existed separately in human and chimpanzee ancestors for the last 5 million years. ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...on (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional inf...

Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome

...al stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to my...

Project Zero Delay Accelerates Drug's Path to Clinical Trial

...tific and human safety review." The key to Zero Delay was performing most tasks in parallel instead of sequentially, said lead author Razelle Kurzroc...Texas M. D. Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and p...

Society of Gynecologic Oncologists Issues White Paper on HPV Vaccine's Impact on Cervical Cancer Prevention

...ducation in gynecologic oncology, our Society is committed to providing the most current data and late-breaking research studies for the good of our subspecialty, our peers, and most importantly, our patients." ABOUT SGO The SGO is a national med...

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

...se (an exacerbation of symptoms) can be managed in most patients with appropriate treatment that includes ...o in the longer-term maintenance study. The most recent acute symptom control study was a multi-cen...ivers and patients. In clinical trials, the most common adverse events (incidence greater than or e...

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

... ProLindac is a novel DACH platinum drug that has shown to be active in many solid tumors in human clinical studies. Platinum drugs are one of the most clinically and commercially successful class of chemotherapies and generated more than $3 billion in revenue globally in 2008. Access believes that P...

Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor

... on Forms 20-F, F-3, F-4 and 6-K, as were filed with the Securities and Exchange Commission (the "SEC") and the Israel Securities Authority and Jazz's most recent filings on Forms 10-K and 10-Q, as were filed with the SEC. Tower and Jazz do not intend to update, and expressly disclaim any obligation to up...

Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA

...re's velaglucerase alfa program is the largest and most comprehensive set of Phase III clinical trials con...rew from the trial due to an adverse event. most of the drug-related adverse events were reported i... disease is an autosomal recessive disease and the most prevalent Lysosomal Storage Disorder (LSD), with a...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

...e risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements wh...

British Woman Celebrates a Year of Living Cancer-Free

... from how she felt when she was diagnosed with acute myeloid leukemia (AML) four years ago. AML is a cancer of the myeloid line of blood cells and the most common acute leukemia among adults. "I was shocked that I had leukemia," Ms. Scott said. "I always ate healthily and exercised and all these s...

Covance Receives Highest Level of Phase I Accreditation

..., United Kingdom, and Switzerland. About Covance Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and mor...